The biopharma world's manufacturing weekly

Endpoints Manufacturing

Manufacturing channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

Subscribe to Endpoints News
Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image:

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Centre” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Up­dat­ed: Catal­ent to cut about 600 jobs in In­di­ana, Mary­land and Texas

Contract manufacturing company Catalent is cutting around 600 jobs in Maryland, Texas, and a major manufacturing facility in Bloomington, IN.

According to a report from a local news site, The Bloomingtonian, the manufacturer announced in an email sent out to employees that it will be cutting 400 positions at the Indiana facility. The company will also cut 77 jobs by Jan. 15 of next year at a cell therapy facility in Webster, TX, just outside of Houston. In Maryland, the company is reducing staff at two locations, with 82 jobs being eliminated at Catalent’s facility in Gaithersburg, and 53 in Rockville. The layoffs go into effect at those locations on Jan. 14.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Fo­s­un Phar­ma con­sid­ers $3.8B sale of In­di­an drug­mak­er Gland Phar­ma — re­port

The Fosun Pharmaceutical Group may be considering the sale of a company it took a stake in just a few years ago.

According to a report from Bloomberg News on Tuesday, Fosun is considering the sale of the Indian-based injectable CDMO Gland Pharma Ltd. after it had reportedly received interest from potential buyers.

Bloomberg said in its report that Fosun has been working with an adviser as it informally “gauges interest” in its controlling stake in Gland. Other companies and buyout firms are in the beginning stages of looking at Gland, but no details have emerged on any potential buyers, the report says. The publication lists the market value of Gland at around $3.8 billion.

Rahul Singhvi, Resilience CEO (Business Wire)

Re­silience pur­chas­es Ohio bio­man­u­fac­tur­ing site from As­traZeneca

Biotech manufacturing pioneer Resilience said Tuesday afternoon that it is purchasing an Ohio-based manufacturing site from AstraZeneca and building a new partnership with the UK-based pharma.

The facility is based in the town of West Chester, OH, just north of Cincinnati. Resilience will produce “select” AstraZeneca medicines at the facility as part of the supply agreement. The financial terms of the agreement weren’t disclosed, but the deal is expected to close early next year.

Sta­da to place $50M+ in­vest­ment in a new fa­cil­i­ty in Ro­ma­nia

While Romania may conjure up images of vast mountain ranges and tales of medieval kings, one generic manufacturer has broken ground on a new facility there.

German pharma company Stada said Monday that it has placed a €50 million ($51.9 million) investment into a 100,000 square-meter (1.08 million square-foot) site in Turda, Romania, a city in the Southeast of the country. According to a Stada spokesperson in an email to Endpoints News, the company has developed only 281,500 square feet of the site so far.

FDA tells Catal­ent to fix is­sues at two man­u­fac­tur­ing sites on its own

The CDMO Catalent will have to fix issues at two manufacturing plants in the US and Europe that were subject to inspections by the FDA this summer, giving the company room to correct the issues without facing further regulatory action.

The FDA gave Catalent a “voluntary action indicated” response to two inspections at the contract manufacturer’s site in Bloomington, IN, and Brussels, Belgium. Fixing the issues on its own is a preferable outcome to facing an “official action indicated” response, meaning that an official warning would be sent out or a sit-down with the FDA would be required.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Post-Brex­it UK trade re­port shows 'wor­ry­ing' signs for life sci­ences

The UK life sciences industry has always been a bright spot for its American trade partners, but a new report from the UK government’s Board of Trade raises some fresh concerns about the UK life sciences in the post-Brexit environment.

The report, published Monday, showed that life science-related trade between the UK and its US and European partners declined, sometimes substantially, over the last five years. For instance, UK life sciences exports from 2016-2021 declined by 17% to Spain, -14% to Italy, -13% to Poland, and -11% to Germany.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Sus­pend­ed Cal­i­for­nia cell ther­a­py man­u­fac­tur­ing site hit with FDA warn­ing let­ter over ma­jor qual­i­ty con­cerns

A cell therapy outfit in California that manufactures a human umbilical cord derived cellular product and exosome products is facing a warning from the FDA over several major observations related to quality.

The FDA notes the site’s “deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing,” and the “risk that your products may be contaminated with microorganisms or have other serious product quality defects.”

Lars Fruergaard Jorgensen, Novo Nordisk CEO (Photographer: Chris Ratcliffe/Bloomberg via Getty Images)

No­vo Nordisk to spend $747M+ on ex­pan­sions and new fa­cil­i­ty in Den­mark

The Danish pharma giant Novo Nordisk is making a major expansion close to home.

The company announced on Tuesday that it plans to invest 5.4 billion Danish kroner ($747.2 million) into expanding its existing facilities in its hometown of Bagsværd, Denmark, a suburb of Copenhagen. Those plans also include the construction of a new plant.

A Novo Nordisk spokesperson did not confirm the size of the new plant to Endpoints News by press time. However, they did tell Endpoints that despite the expansion of existing facilities, the manufacturing of active pharmaceutical ingredients (API) is currently ongoing to support clinical trials. The expansions are expected to be finalized and fully operational in August of next year for purification. The new facility, which is centered around fermentation and recovery, is expected to be finalized in August 2024.